English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
2024-02-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
2024-02-06
VOLUNTARY ANNOUNCEMENT - LICENSE AGREEMENT WITH 3D MEDICINES AND GLENMARK FOR KN035
2024-01-25
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
2024-01-04
EXTENSION OF WAIVER REGARDING THE QUALIFICATION AND EXPERIENCE OF A JOINT COMPANY SECRETARY
2023-12-19
VOLUNTARY ANNOUNCEMENT - A PHASE I/II CLINICAL TRIAL OF JSKN033 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED OR METASTATIC SOLID TUMORS WAS APPROVED IN AUSTRALIA
2023-12-08
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF RESEARCH UPDATES ON KN026 AT THE SABCS 2023
2023-12-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
2023-12-05
Next Day Disclosure Return
2023-11-28
VOLUNTARY ANNOUNCEMENT - CLARIFICATION
2023-11-24
4
5
6
7
8
9
10
PREV
7/27
NEXT